Washington University Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer
January 06, 2016 at 07:53 AM EST
Verastem, Inc. (NASDAQ: VSTM) today announced the initiation of a Phase 1 dose-escalation study at Washington ...
